Newly Diagnosed AML: Antileukemic Therapy or Best Supportive Care?
In patients with newly diagnosed acute myeloid leukemia who are candidates for active treatment, a central clinical decision is whether to pursue antileukemic therapy (ALT) rather than best supportive care alone.
Treatment approach
Evidence supports offering antileukemic therapy over best supportive care only. The complete protocol details the eligible patient population, the available therapeutic options, and the criteria guiding selection.
References
DOI: 10.1182/bloodadvances.2025017934
For older adults with newly diagnosed AML who are candidates for ALT, the ASH guideline panel recommends offering ALT over best supportive care (strong recommendation based on moderate certainty in the evidence of effects ⊕⊕⊕○).
View source ↗